Lund April 5, 2017
Completing the Nomination Committee's in Enzymatica AB proposal for AGM 2017 regarding election of auditor
The audit tender process is completed and the Nomination Committee proposes election of auditor in accordance with the following.
Proposal under item 12 in the notice convening the annual general meeting: The Nomination Committee proposes election of Deloitte AB as new auditor for a mandate period of one year. In the event Deloitte AB is elected, the accounting firm has informed that the authorized public accountant Per-Arne Pettersson will be auditor in charge. The Nomination Committee proposes that the auditors will be paid according to approved invoice.
According to the decision of the AGM 2016, the Nomination Committee shall consist of the Chairman and one representative for each of the four largest shareholders at the end of October every year. The Nomination Committee prior to the AGM 2017 comprises Håkan Roos, representing Abanico Invest AB, Guðmundur Pálmason representing Protenus Holding Ltd., Águstá Guðmundsdóttir representing Gadice ehf. and Björn Algkvist, representing Fibonacci Asset Management AB.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: firstname.lastname@example.org
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on eight markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymaticas Certified Adviser is Erik Penser Bank.